Navigation Links
ARIUS sale approved by shareholders
Date:9/18/2008

1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... -- Reportbuyer.com has added a new market research ... Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... similar amount of hype currently surrounds graphene, with ... water treatment, but is graphene the only solution? ... Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
Breaking Biology Technology:DTU researchers film protein quake for the first time 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... been proposed for regenerative medicine and tissue replacement after ... to efficiently develop into the desired specific cell type ... neurons now limits the potential clinical utility of ... within aggregates of embryonic stem cells via biodegradable microspheres ...
... Ill., April 9 Baxter Healthcare Corporation,today ... VitalShield,protective coating, the first needleless intravenous (IV) ... available for hospitals in the,United States and ... to kill on,average 99.9 percent or more ...
... April 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... its U.K. combination REOLYSIN(R) and carboplatin/paclitaxel,trial. Dr. ... Research, London,and the principal investigator for the ... Annual Conference of the British Society for ...
Cached Biology Technology:Method to deliver molecules within embryonic stem cells improves differentiation 2Method to deliver molecules within embryonic stem cells improves differentiation 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 3
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
(Date:8/27/2014)... often depicted as giant, frightening beasts. But every creature ... a rock slab containing fossils of 24 very young ... group of hatchlings overseen by a caretaker, according to ... Penn,s Brandon P. Hedrick and Peter Dodson led the ... Natural History, where the specimen is held. Hedrick is ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... National Institutes of Health (NIH) announced today a new ... articles resulting from NIH-funded research. The policy ?the first ... release to the public manuscripts from research supported by ... of final publication. , These peer-reviewed, NIH-funded research publications ...
... Medical School, demonstrating how malaria parasites form mutations that ... the key to a new treatments for a disease ... , The scientists developed disease models using yeast and ... the anti-malarial drug, atovaquone. The study, featured as the ...
... for humans and most animals but not Australia's green-striped ... University of Queensland has found that unlike most animals, ... the green-striped burrowing frog is able to absorb nutrients ... than frogs that had eaten regularly. , "They can ...
Cached Biology News:NIH Calls on Scientists to Speed Public Release of Research Publications 2NIH Calls on Scientists to Speed Public Release of Research Publications 3Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: